Roadmap to personalized medicine

Croatian Medical Journal

Volumn 53, Issue 4, 2012, Pages 294-297

  Qattan, Malak ^a   Demonacos, Constantinos ^a   Krstic Demonacos, Marija ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; CYTOCHROME P450 2E1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL PROTOCOL; DRUG METABOLISM; GENE REARRANGEMENT; HEALTH CARE COST; HEALTH INSURANCE; HEALTH PRACTITIONER; HUMAN; INDIVIDUALIZATION; INTERNATIONAL NORMALIZED RATIO; LIFESTYLE; LUNG NON SMALL CELL CANCER; MEDICAL EDUCATION; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENOMICS; SOCIOECONOMICS;

BIOMEDICAL RESEARCH; COMPUTATIONAL BIOLOGY; DATA MINING; DRUG DESIGN; EDUCATION, MEDICAL; HUMANS; INDIVIDUALIZED MEDICINE; INFORMATION DISSEMINATION; INTERDISCIPLINARY COMMUNICATION; RESEARCH DESIGN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84866461311     PISSN: 03539504     EISSN: 13328166     Source Type: Journal    
DOI: 10.3325/cmj.2012.53.294     Document Type: Article

References (20)

1. Louca S, Pochet R, Schinzer D. Why another conference on personalized medicine? Croat Med J. 2012;53:205-6.
2. Ginsburg GS, McCarthy JJ. Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 2001;19:491-6.
3. Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab. 2011;12:487-97.
4. Chen G, Kronenberger P, Teugels E, Umelo IA, De Greve J. Targeting the epidermal growth factor receptor in non-small cell lung cancercells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med. 2012;10:28.
5. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8:11-23.
6. Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011;17:2081-6.
7. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009;27:5838-47.
8. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329-33.
9. Ades F, Metzger-Filho O. Targeting the cellular signaling: BRAF inhibition and beyond for the treatment of metastatic malignant melanoma. Dermatol Res Pract. 2012;2012:259170.
10. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7:201-4.
11. Karas-Kuzelicki N, Mlinaric-Rascan I. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond. Pharmacogenomics. 2009;10:1309-22.
12. Louca S. Personalized medicine - a tailored health care system: challenges and opportunities. Croat Med J. 2012;53:211-3.
13. Henney AM. The promise and challenge of personalized medicine: aging populations, complex diseases, and unmet medical need. Croat Med J. 2012;53:207-10.
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
15. Leung T, Alavi H, Andreou K, Krstic-Demonacos M, Demonacos C. The role of cytochromes P450 in cancer and their potential as targets for anti-cancer drug development. Int J Mol Med. 2011;28:S69.
16. Vaclavikova R, Hubackova M, Stribrna-Sarmanova J, Kodet R, Mrhalova M, Novotny J, et al. RNA expression of cytochrome P450 in breast cancer patients. Anticancer Res. 2007;27:4443-50.
17. Chen DW, Lynch JT, Demonacos C, Krstic-Demonacos M, Schwartz JM. Quantitative analysis and modeling of glucocorticoidcontrolled gene expression. Pharmacogenomics. 2010;11:1545-60.
18. Chen DW, Liu JZ, Saha V, Schwartz JM, Krstic-Demonacos M. Erg and AP-1 as determinants of glucocorticoid response in acute lymphoblastic leukemia. Oncogene. 2012.
19. Haiech J, Kilhoffer MC. Personalized medicine and education: the challenge. Croat Med J. 2012;53:298-300.
20. Duburs G, Neibecker D, Zarkovic N. Chemistry and personalised medicine - the research and development future of Europe. Croat Med J. 2012;53:291-3.